Hansa Biopharma partners with Cradle for AI-driven protein design in autoimmune therapies

Hansa Biopharma announced a collaboration with Cradle to apply AI-driven protein design to develop new immunomodulatory treatments for autoimmune diseases. The deal is early-stage and financial terms are undisclosed. It signals continued industry adoption of AI in drug discovery, but no clinical or commercial impact is imminent.